上海医药：子公司盐酸索他洛尔片通过仿制药一致性评价

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Changzhou Pharmaceutical Factory, received the approval notice for the supplementary application of Sotalol Hydrochloride Tablets from the National Medical Products Administration, indicating that the drug has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The approval of Sotalol Hydrochloride Tablets is expected to expand the market share of the drug and enhance its market competitiveness [1] - The drug's market performance may be affected by uncertainties related to national policies and market conditions, leading to potential sales not meeting expectations [1]